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One feature revealed by extensive investigations on airway smooth muscle over the last two decades is that smooth muscle length-tension curves may undergo acute length adaptation. That is, rather than being static, as in striated muscle, the active length-tension curve in certain smooth muscles shifts along the length axis due to accommodation of the muscle at different lengths (4) . Although the precise mechanism for length adaptation remains to be fully elucidated, one model that has gained some traction is that length adaptation involves contractile unit and cytoskeletal rearrangements and contractile apparatus reshaping (7, 10, 14) .
Far fewer studies have investigated the hypothesis that smooth muscles other than airway smooth muscle undergo length adaptation. Recent studies from our laboratory (35) (36) (37) (38) support the notion that the urinary bladder displays extensive plasticity in both passive and active length-tension curves. This seems logical given that the bladder's working length range encompasses an approximate sevenfold length change from ϳ35% to Ͼ200% of a reference length (43) . Arterial smooth muscle has a shorter working length range than does bladder smooth muscle (13) , so one might anticipate that arterial smooth muscle does not have a physiological requirement to length adapt. In support of this notion, studies (13, 46) on swine carotid media have shown that length-tension curves in vascular smooth muscle are likely static. To the contrary, Seow and collegues (32, 39) have shown that carotid and pulmonary arteries can display some degree of length adaptation. Moreover, although length adaptation was not explicitly examined, early studies on large (34) and small (21) mesenteric arteries have provided evidence for some degree of dynamic behavior in vascular smooth muscle length-tension curves.
A basic tenant of striated muscle biology is that the strength of active tension is determined by the number of attached cross-bridges additively generating positive force that is transmitted through intracellular and extracellular force-bearing structures in series with cross-bridges (19) . In arterial smooth muscle, cross-bridges can be "turned on" in a graded fashion. Thus, the degree of active tension generated by arterial smooth muscle is dependent on the regulation of muscle activation as well as on cross-bridge geometry and structures linking crossbridges to cytoskeletal and extracellular proteins. Because activation mechanisms may display length-dependent regulation (23, 44) due to changes in Ca 2ϩ mobilization (30) , Ca 2ϩ sensitivity (20) , and possibly agonist-receptor coupling (41) , the plasticity of smooth muscle active length-tension curves may be due to length-dependent changes in the level of cross-bridge activation. Smooth muscle cross-bridge activation is subject to rather extensive control involving both thick and thin filament regulatory proteins (12) , and a protein kinase network regulates the rates of phosphorylation and dephosphorylation of myosin light chain (MLC) at the thick filaments (15) . An additional complexity is that cross-links other than cross-bridges may participate in bearing some of the load during active tension maintenance (18, 24, 40) . The present study was designed to further investigate length adaptation in arterial smooth muscle. We asked the following specific question: Is the strength of active tension generated during the first isometric muscle stimulation episode after release of a muscle to a shorter length the same as or different than the strength achieved by several subsequent stimulation episodes? We used membrane depolarization (KCl) in the presence of ␣-adrenergic receptor blockade as the stimulus to bypass receptor activation and simplified our analysis by avoiding potential G protein-coupled receptor up-and downregulation. Moreover, KCl-induced contractions are temporally biphasic, and because the early (phasic) and delayed (tonic) phases depend on different activation mechanisms (42, 47) , we examined whether length adaptation was selective for one or the other contractile phase. To determine whether changes in cross-bridge activation played a role in length adaptation, we examined potential changes in resting and KCl-stimulated MLC phosphorylation. Finally, we measured the effects of actin polymerization inhibition and Rho kinase (ROCK) inhibition on length adaptation.
MATERIALS AND METHODS
Tissue preparation. Femoral arteries were removed from adult New Zealand White rabbits immediately after the animals had been killed as designated by a protocol approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee. Tissues were prepared as previously described (25) . In brief, femoral arteries were carefully dissected from both hind legs, cleaned of adhering tissue, and used immediately or stored in modified physiological salt solution (PSS) at 0 -4°C for no more than 2 days for later experimentation. The PSS composition was 140 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.6 mM CaCl2, 1.2 mM Na2HPO4, 2.0 mM MOPS (adjusted to pH 7.4), 0.02 mM EDTA (to chelate heavy metals), and 5.6 mM D-glucose. Immediately before an experiment, the endothelium was mechanically disrupted by passing a roughened metal rod through the lumen several times, and the artery was cut into rings ranging from 3 to 4 mm in length. Each arterial ring was secured between two pins in an aerated tissue chamber (Danish Myo Technology, Aarhus, Denmark, and Radnoti Glass Technology, Monrovia, CA) containing PSS maintained at 37°C. One pin was connected to a micrometer for length adjustments, and the other pin was connected to an isometric tension transducer. Each tissue was stretched immediately to 0.5 g, allowed to equilibrate for 1 h, and then subjected to an abbreviated length-tension protocol to identify L 0 using K ϩ depolarization (KCl; 110 mM substituted isosmotically for NaCl) to activate the muscle using the method originally described by Herlihy and Murphy (13) for the swine carotid artery and subsequently used by our laboratory (25, 26) for rabbit femoral and renal arteries. The optimum active tension of muscle contraction (T0) at L0 was equal to the steady-state (10 min) total tension value minus the passive tension measured just before activation with KCl. This passive tension value (preload) was subtracted from total tension for all subsequent contractions, and, unless otherwise indicated, tension values were reported as T/T 0. That is, a T/T0 value of 0 would indicate that the muscle was "at rest" and at L 0, and a T/T0 value of 1 would indicate that tension was equivalent to the steady-state active tension induced by KCl at L0. Arteries contracted with KCl were incubated with 1 M phentolamine to block potential ␣-adrenergic receptor activation caused by the potential release of norepinephrine from periarterial nerves. Tension data were acquired through an analog-to-digital conversion board (National Instruments, Austin, TX) and analyzed using DasyLab 8.0 (DasyTech, Amherst, NH).
Western blot analysis. Phosphorylation of 20-kDa MLCs was measured by Western blot analysis of artery ring homogenates. Artery rings at 0.75-and 1.25-fold L0 and at basal and steady-state contraction were quick frozen in an acetone-dry ice slurry, thawed to room temperature in an acetone mixture with 6% trichloroacetic acid, 10 mM DTT, and 30 mM NaF, homogenized in a buffer containing 1% SDS, 10% glycerol, 20 mM DTT, 25 mM Tris·HCl (pH 6.8), 5 mM EGTA, 1 mM EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 20 g/ml leupeptin, 20 g/ml aprotinin, and 20 g/ml (4-amidinophenyl)-methane-sulfonyl fluoride, heated, clarified by centrifugation, and stored at Ϫ20°C or immediately assayed for protein concentration. Proteins were separated by electrophoresis followed by Western blot analysis. MLC phosphorylation was identified using a rabbit polyclonal antibody specific for 20-kDa MLC phosphorylated at Ser 19 (Sigma, St. Louis, MO). Quantification of total 20-kDa MLC was assessed using an anti-20-kDa MLC mouse monoclonal antibody (Sigma) to ensure accuracy of equivalent loading of lanes. To assess whether length adaptation of tension occurs with or without a concomitant increase in MLC phosphorylation, the amount of MLC phosphorylation and tension produced at 10 min of contraction during a third stimulation with KCl after release to a short muscle length were divided by those values produced at 10 min of contraction during a first stimulation with KCl after release to a short muscle length (see Fig. 3 ). A ratio of Ͼ1 would indicate that the degree of MLC phosphorylation and/or tension produced during the third KCl stimulation was greater than that produced during the first. Ratios produced under basal conditions just before stimulation with KCl were also measured. For a comparison, ratios also were measured in tissues that had been stimulated multiple times without being released to a shorter muscle length (see Fig. 3 ).
Protocol for length adaptation at a shortened muscle length. After the determination of L0 through an abbreviated length-tension curve protocol, tissues were maintained either at L 0 or released to a shortened length of 0.8-fold L0 for 5 min. The release was accomplished manually by turning the micrometer attached to one of the pins that attached to the artery ring, and the step reduction in length was usually completed within ϳ1 s. Because data were presented as tension at the new muscle length (0.8-fold L0) normalized to active tension at L0, the resulting resting T/T 0 values were negative numbers (for example, see Fig. 1A ). Tissues were then subjected to three contraction-relaxation cycles by contraction with KCl for 10 min and relaxation by KCl washout (using PSS) for 15 min. The rabbit femoral artery stimulated with KCl produces a rapid contraction that peaks within ϳ15 s followed by a slower rise in tension to a pseudosteady state within ϳ3 min (29) . Tension generally declines slowly by a few percent to reach a new sustained steady state within 10 min or remains at this higher level for many minutes without decline. To assess the effects of a reduction in muscle length on tension induced by KCl, both early peak (phasic) and 10 min steady-state (tonic) tension values were recorded and compared.
Drugs. Phentolamine and nifedipine were from Sigma. Latrunculin-B, cytochalasin-D, and H-1152 were from Calbiochem (La Jolla, CA). Nifedipine was dissolved in ethanol, latrunculin B and cytochalasin-D were dissolved in DMSO, and phentolamine and H-1152 were dissolved in deionized water. Ethanol and DMSO were added at a final concentration no greater than 0.1%, which had no effect on tension (22) .
Statistical analysis. Statistical comparisons were evaluated using either Excel 2003 (Microsoft, Redmond, WA) or Prism 3.0 (GraphPad Software, San Diego, CA). The null hypothesis was examined using Student's t-test (when two groups were compared) or using one-way ANOVA (when more than two groups were compared). To determine differences between groups after ANOVA, Student-Newman-Keuls or Dunnett's (when comparing test groups with the control group only) post hoc tests were used. The null hypothesis was rejected at P Ͻ 0.05. For each experiment described, the n value was equal to the number of rabbits used in the study.
RESULTS
Active tension adaptation at a shortened muscle length. To determine whether active tension in the femoral artery is a constant or constrained variable at each muscle length, tissues at L 0 were rapidly (ϳ1 s) released to 0.8-fold L 0 and, after ϳ5 min at the new length, contracted with KCl to determine the strength of active tension that was initially produced at 0.8-fold L 0 . This first contraction at 0.8-fold L 0 was termed T 1 . As explained in MATERIALS AND METHODS, a T/T 0 value of 0 indicates that the muscle tension is equal to the preload (passive or unstimulated) tension at L 0 , and a T/T 0 value of 1 indicates that tension is equal to steady-state KCl-induced active tension at L 0 . A 20% length shortening (length step from L 0 to 0.8-fold L 0 ; Fig. 1A, top) reduced the preload by ϳ10% (to approximately Ϫ0.1 T/T 0 ; Fig. 1A , bottom) and should likewise reduce the degree of active tension that can be induced by KCl because the muscle should now be on the ascending limb of its length-tension curve rather than at its maximum. This was found to be the case because the T/T 0 value at 0.8-fold L 0 for the tonic phase of the KCl-induced T 1 contraction was ϳ80% (Fig. 1B, contraction 1) . That is, the 20% reduction in length from L 0 to 0.8-fold L 0 reduced passive tension by ϳ10% and, after a single KCl-induced contraction (T 1 ), reduced steadystate active tension by ϳ20%.
Two subsequent contractions (T 2 and T 3 ) produced greater phasic and tonic T/T 0 values compared with those induced by the T 1 contraction (Fig. 1, A, bottom, and B) , but passive tension did not change. T 4 and T 5 contractions did not permit further improvement in active tension above that induced by the T 3 contraction (Fig. 1B) . These data suggest that the rabbit femoral artery can undergo length adaptation in active tension and that three contractions produced subsequent to a 20% reduction in muscle length can cause this improvement in the strength of contraction.
Because the T 5 contraction was not improved compared with the T 3 contraction, we reasoned that three contractions were sufficient to induce length adaptation, and most subsequent experiments assessed length adaptation by comparing the third (T 3 ) and first (T 1 ) contractions produced by KCl subsequent to an imposed reduction in muscle length. To account for any small change that may have occurred in passive tension over time, the active tensions produced during the T 1 , T 2 , and T 3 KCl-induced contractions were computed by subtracting the passive tension measured just before each KCl-induced stimulation from the total tension for each stimulation. The active tensions for stimulations T 2 and T 3 were then normalized to that induced by T 1 , and these values represented the fractional improvement in active tension. Interestingly, the peak contraction (phasic phase tension; Fig. 1C ) improved more than that at 10 min of contraction (tonic phase tension; Fig. 1D ).
Active tension adaptation at a shortened muscle length requires contraction. The signal that initiates adaptation may be the change in muscle length or contraction at the new muscle length. To determine which of these signals was responsible for length adaptation, we subjected tissues to two different time-dependent protocols and compared the strengths of the tonic phase of KCl-induced contractions induced after release from L 0 to 0.8-fold L 0 . One set of tissues was contracted ϳ5 min after release [ Fig. 2A (T 1 )] and then four more times so that the fifth contraction was stronger [adapted to the . The second set of tissues was not contracted until ϳ110 min had elapsed after the release so that the contraction, T 1,delay , corresponded in time with the fifth contraction of the first group of tissues (Fig.  2B) . The tonic phase of the KCl-induced T 1,delay contraction was not different from that induced by the T 1 contraction. Thus, these data support the notion that activation of contraction was required to induce length adaptation.
Role of MLC phosphorylation in length adaptation. A major form of rapid regulation of active tension in smooth muscle involves changes in the degree of MLC phosphorylation. To determine whether regulation of MLC phosphorylation was responsible for the improvement in active tension induced by three sequential stimulations with KCl subsequent to an imposed step decrease in muscle length (i.e., length adaptation), tissues were subjected to a protocol similar to that shown in Fig. 1A except that three rather than five contractions were induced after tissues were released to a shorter muscle length. Very small changes in MLC phosphorylation can produce quite large changes in tension (27) . Moreover, MLC phosphorylation assays are tissue destructive, so MLC phosphorylation during a first and third contraction cannot be compared in a single tissue. Therefore, to capture the potentially very small difference in MLC phosphorylation that would be expected to account for an ϳ10% improvement in active tonic tension, tissues were subjected to a greater length change in an attempt to enhance the degree of adaptation produced. Moreover, certain precautions were taken to minimize tissue variability. In particular, for each n value of this experiment, four adjacent muscle rings were cut from one femoral artery and four from the second artery. Four rings were subjected to the protocol shown in Fig. 3A ; the other four rings were used in the protocol shown in Fig. 3B . After all eight tissues were streched from L 0 to 1.25-fold L 0 and contracted three times to potentially adapt to the new longer muscle length, four tissues were released to 0.75-fold L 0 and the other four remained at 1.25-fold L 0 . One of the four tissues was frozen at ϳ5 min to record the basal level of MLC phosphorylation at 0.75-fold L 0 before a first stimulation with KCl [ Fig. 3A , bottom (first solid circle at ϳ120 min)]. The remaining three tissues were contracted with KCl, and one of the three tissues was frozen at 10 min to record the level of MLC phosphorylation during the T 1 contraction [Fig. 3A , bottom (second solid circle just below T 1 )]. The remaining two tissues were relaxed, contracted a second time with KCl, and relaxed, and the third tissue was frozen to record the basal level of MLC phosphorylation at 0.75-fold L 0 before the third stimulation with KCl [ Fig. 3A, bottom (third solid  circle) ]. The remaining tissue was contracted a third time (T 3 ) with KCl and frozen at 10 min to record the potential improvement in MLC phosphorylation compared with the level ex- pected during the T 1 contraction [Fig. 3A , bottom (fourth solid circle just below T 3 )]. The other four tissues were treated similarly, but tissues were not released from 1.25-fold L 0 to the shorter length (Fig. 3B) .
Active tension and MLC phosphorylation T 3 -to-T 1 ratios were compared as a means to more clearly delineate small differences. As expected based on the experiment shown in Fig. 1 , active steady-state tension induced by the T 3 contraction in muscle released to 0.75-fold L 0 was significantly greater than that induced by the T 1 contraction. Interestingly, rather than an ϳ10% increase in tonic tension induced by the protocol shown in Fig. 1A (release from L 0 to 0.8-fold L 0 ), the protocol used in this experiment (release from 1.25-to 0.75-fold L 0 ) induced an ϳ50% increase in tonic tension when the third and first contractions were compared [i.e., the T 3 -to-T 1 active tension ratio was ϳ1.5; Fig. 3C (tension; crosshatched bar) ]. Resting tension just before the T 3 contraction was not greater than resting tension just before the T 1 contraction [i.e., the T 3 -to-T 1 basal tension ratio was not different than 1; Fig. 3C (tension; open bar)]. Although active tension was 50% greater, the degree of MLC phosphorylation induced at 10 min of the T 3 KCl-induced contraction was not greater than that induced at 10 min of the T 1 KCl-induced contraction [i.e., the T 3 -to-T 1 MLC phosphorylation ratio was not different than 1; Fig Neither tension nor MLC phosphorylation induced by the T 3 contraction at 1.25-fold L 0 were greater than the respective values induced by the T 1 contraction [ Fig. 3D (crosshatched  bars)] . Surprisingly, passive tension and basal MLC phosphorylation declined when values taken just before the T 3 contraction were compared with those taken just before the T 1 contraction in tissues maintained at 1.25-fold L 0 . This reduction in basal values with time at 1.25-fold L 0 does not explain the increase in tension produced when an artery ring is released to a shorter muscle length and contracted three times. However, it may provide insight into another form of adaptation that appears to occur at long muscle lengths. This finding was not further pursued in this study. In summary, the 50% increase in tonic active tension generated with repeated contractions at a shortened muscle length cannot be explained by regulation of MLC phosphorylation at Ser 19 .
Effect of actin polymerization inhibitors and of ROCK inhibition on length adaptation.
Before assessing the effect of actin polymerization and ROCK inhibitors on length adaptation, the effect of cytochalasin-D, latrunculin-B, and H-1152 on multiple contractions was measured. Interestingly, addition of the actin plus end polymerization inhibitor cytochalasin-D (0.2 M) to tissues between contractions T 1 and T 2 not only inhibited the phasic (Fig. 4A) and tonic (Fig. 4A) phases of a KCl-induced contraction but also produced an apparent usedependent enhancement of inhibition of subsequent KCl-induced contractions (Fig. 4, A and D) . In particular, the first KCl-induced contraction subsequent to exposure to cytochalasin-D (T 2 ) was inhibited by ϳ20%, whereas the fifth KClinduced contraction (T 6 ) after exposure to cytochalasin-D was inhibited by ϳ60 -70% (Fig. 4D) . The tonic phase of contraction was inhibited only slightly more than the phasic phase of contraction (Fig. 4D) . A similar response was obtained when availability of the G-actin monomer for utilization in building F-actin polymers was impeded by exposure of tissues to 2 M latrunculin-B (Fig. 4, B and E) . A notable difference between cytochalasin-D and latrunculin-B was that the latter produced a more dramatic (nearly 70%) inhibition of the tonic phase of the T 2 contraction than the former [see Fig. 4E (T 2 /T 0 , Tn)]. As we have previously reported (42), the ROCK inhibitor H-1152 (0.3 M) reduced the tonic phase but not the phasic phase of a KCl-induced contraction (Fig. 4, C and F) . Moreover, unlike the actin polymerization inhibitors, H-1152 did not display an apparent use-dependent enhancement of inhibitory activity (the T 6 contraction was not weaker than the T 2 contraction; Fig. 4,  C and F) .
Each of the drugs we chose inhibits contraction, and our goal was to determine whether the drug would also inhibit the increase in tension produced when tissues were contracted three times after being released from L 0 to 0.8-fold L 0 . Thus, responses produced upon release from L 0 to 0.8-fold L 0 and normalized to time-dependent responses produced at L 0 in the drug-treated tissues were compared with control tissues not drug treated (Fig. 5) . Cytochalasin-D not only inhibited a KCl-induced contraction in tissues at L 0 (Fig. 5A, middle top) but also prevented length adaptation induced by release of tissues from L 0 to 0.8-fold L 0 (Fig. 5A, bottom) . Cytochalasin-D inhibited length adaptation observed both in the phasic (Fig. 5C) and tonic (Fig. 5D) phases of a KCl-induced contraction. That is, the strength of the third contraction induced after the release from L 0 to 0.8-fold L 0 (T 3 ; Fig. 5A, bottom) was not greater than the strength of the first contraction (T 1 ; Fig. 5A, bottom) . Because the data shown in Fig. 5 , C and D accounted for the steady decline in strength of a KCl contraction with each subsequent stimulation, inhibition of length adaptation could not be ascribed to the apparent use-dependent effect of cytochalasin-D (greater inhibition of contraction observed with every subsequent contraction).
Also examined for comparison was the ability of a relatively low concentration (10 nM) of the Ca 2ϩ channel blocker nifedipine to inhibit length adaptation. Nifedipine strongly inhibited the tonic phase of a KCl-induced contraction (Fig. 5B , middle top) but did not inhibit length adaptation (Fig. 5, B, bottom, and  C and D) . That is, the strength of the third contraction induced after the release from L 0 to 0.8-fold L 0 (T 3 ; Fig. 5B, bottom) was greater than the strength of the first contraction (T 1 ; Fig.  5B, bottom) . As with H-1152, nifedipine did not induce an apparent use dependency (Fig. 5B, middle top) .
Unlike cytochalasin-D, latrunculin-B, H-1152, and nifedipine did not inhibit length adaptation of the phasic phase of a KCl-induced contraction (Fig. 5C) . In fact, latrunculin-B actually enhanced length adaptation of the phasic phase of contraction (Fig. 5C) . Because of the high degree of variability in the data, the results for the tonic phase of a KCl-induced contraction were more ambiguous. In short, some tissues appeared to display length adaptation and others did not, so the SEs were quite large (Fig. 5D) . The data were not statistically different than the control when assessed using ANOVA and Dunnett tests. However, a Student's t-test indicated that, although the control data were significantly greater than zero, the latrunculin-B and H-1152 data were not (Fig. 5D) . Together, these data suggest that for the phasic phase improvement of contraction during length adaptation to occur, actin polymerization at the plus end is required, but free G-actin monomers, ROCK, and elevated Ca 2ϩ levels are not required. Tonic phase improvement of contraction required actin polymerization and not Ca 2ϩ entry through nifedipine-sensitive channels. Whether ROCK or G-actin monomers were required could not be ascertained.
DISCUSSION
We show in this study that the strength of an active KClinduced contraction of the femoral artery shortened by 20% from L 0 to 0.8-fold L 0 was reduced by ϳ10% and that the subsequent application of two more sequential KCl-induced contractions led to an adaptive strengthening of the muscle active tension such that the phasic and tonic phases of contraction improved by, respectively, ϳ15% and ϳ10% compared with the first contraction. A greater change in length resulted in a greater improvement (for example, a third contraction induced after shortening from 1.25 to 0.75 L o resulted in an ϳ50% improvement in contractile strength). This improvement in active tension was not due to regulation of myosin cross-bridge phosphorylation, Ca 2ϩ entry through voltageoperated Ca 2ϩ channels, or ROCK activity, but appeared to be highly dependent on actin polymerization. Also, our data suggest that length adaptation was not initiated solely by the length change, as has been suggested for the carotid artery (32) , but required at most three brief (10 min) sequential contractions. Whether a single, prolonged contraction lasting the duration of the three relatively brief sequential contractions would be sufficient to induce adaptation at the new, shorter muscle length was not determined. Together, these data suggest that the active length-tension curve for the rabbit femoral artery displays both length-history and activation-history dependencies. Moreover, our data support the notion that the phasic and tonic phases of vascular smooth muscle contractions are not identical, possibly reflecting certain differences in activation mechanisms (42, 47) .
It is now generally accepted that length adaptation occurs in airway smooth muscle (4) . There are compelling physiological reasons for expecting that length adaptation should also occur in other smooth muscle types, especially those that undergo dramatic length changes. In this regard, length adaptation has been recently shown to occur in rabbit bladder smooth muscle (35) , although reports of this phenomenon have been generated by one laboratory only. Large elastic arteries such as carotid and pulmonary arteries also undergo periodic length changes in response to ventricular ejection (1), and rabbit carotid and sheep pulmonary arteries have been recently shown to undergo length adaptation (32, 39) . The present study confirms and extends these earlier studies on large elastic arteries to show that the rabbit femoral artery, a large muscular artery, also undergoes length adaptation. Whereas the mechanism responsible for length adaptation in elastic arteries has not been determined, several studies (7, 10, 14) support the notion that in airway smooth muscle, length adaptation involves contractile unit and cytoskeletal rearrangements and contractile apparatus reshaping. Our study supports the notion that rearrangement or reshaping of the contractile apparatus rather than modulation of cross-bridge activation was most likely responsible for length adaptation in the femoral artery.
Because myosin phosphorylation was not enhanced, the increase in the strength of active tension induced by three sequential KCl-induced contractions in a muscle shortened to ϳ0.8-fold L 0 was likely not caused by additional activation of MLC kinase. These data are supported by our finding that partial Ca 2ϩ entry blockade using nifedipine did not inhibit length adaptation. Moreover, our data using the ROCK blocker H-1152, along with the finding that myosin phosphorylation was not increased, supports the notion that ROCK did not play a role in length adaptation. Together, these data suggest that thick filament regulation was not involved in length adaptation in the rabbit femoral artery. Although our data cannot rule out the possibility that thin filament regulatory proteins may have participated in an increase in the number of active crossbridges, the complete inhibition of length adaptation by cytochalasin-D supports the notion that actin polymerization rather than actin-dependent cross-bridge regulation played a key role in causing length adaptation.
The notion that actin polymerization plays a role in smooth muscle contraction is becoming more widely accepted (11) . Wright (47) showed in 1994 that inhibition of actin polymerization by cytochalasin-D selectively reduces the tonic phase of a KCl-induced contraction of the rat aorta. Saito et al. (31) confirmed this study and further showed that inhibition of contraction by cytochalasin-D did not involve a reduction in intracellular Ca 2ϩ concentration or MLC phosphorylation. Because cytochalasin-D inhibited superprecipitation of actomyosin, these authors proposed that inhibition of actin polymerization can reduce the number of activated cross-bridges. Our data confirmed that cytochalasin-D inhibits a KCl-induced contraction, but unlike in the rat aorta, where cytochalasin-D inhibits only the tonic phase of contraction, cytochalasin-D inhibited both phasic and tonic phases of contraction in the muscular femoral artery. Notably, we found that inhibition of contraction by the actin polymerization inhibitors cytochalasin-D and latrunculin-B displayed use dependency. This was not found for nifedipine and H-1152, suggesting that actin polymerization may have a cumulative effect on contraction. In addition to inhibiting contraction itself, we found that cytochalasin-D abolished length adaptation.
Latrunculin selectively inhibits contractions of the ferret aorta induced by phenylephrine and phorbol ester but not KCl (17) . These data suggest that cell signaling involving PKC may play a role in cytoskeletal remodeling in this artery. PKC participates in the KCl-induced contraction of the rabbit femoral artery (28) , and we found that latrunculin, like cytochalasin-D, inhibited both phasic and tonic phases of a KCl-induced contraction in this artery. However, unlike cytochalasin-D, latrunculin did not inhibit length adaptation of the phasic phase of a KCl-induced contraction. Whether it inhibited the tonic phase could not be ascertained by our protocol. Because latrunculin reduces the extension of actin polymerization by binding free actin monomers (G-actin), our data suggest that length adaptation involved the direct utilization of a pool of sequestered G-actin (48) .
The present study supports the hypothesis that the lengthtension relationship of arterial smooth muscle is dynamic. We propose that dynamic length-tension regulation provides a means for arterial muscle to broaden the length range at which active force is maximum. This process may provide stability in regulation of arterial stiffness, a key parameter affecting pulse wave velocity, and, therefore, pulse pressure (3). In particular, an increase in active tension at a given muscle length will necessarily shift load away from noncompliant extracellular matrix proteins to more compliant smooth muscle. This would tend to increase the damping function of the artery (2), thus reducing arterial stiffness. There is now compelling evidence that large artery stiffness is a major factor in determining cardiovascular morbidity and mortality (8, 49) . Understanding large artery length adaptation may provide novel molecular insights into the regulation of large artery stiffness.
In summary, our data showed that passively shortening the rabbit femoral artery by 20% followed by actively contracting the muscle initiates an adaptive response leading to enhancement of active tension by ϳ10 -15%. Shortening by 50% followed by active contractions resulted in an ϳ50% adaptive increase in active tension. Actin polymerization played a key role in this length adaptation, and activation of myosin phosphorylation was ruled out. Whether the increase in active tension generated by actin polymerization was due to adding more activated cross-bridges in parallel to existing crossbridges or to structural changes possibly involving stiffening of the cytoskeleton without changes in the number of active cross-bridges is a question that remains to be answered. A more thorough understanding of length adaptation of the femoral artery may provide novel insight into mechanisms causing reduced compliance of large arteries in hypertension (1) .
